valproic acid and lamotrigine

Valproic acid inhibits the glucuronidation of lamotrigine, principally via inhibition of UDP-glucuronosyltransferase (UGT) enzymes. This results in a marked reduction in lamotrigine clearance, approximately doubling its plasma half-life and increasing steady-state concentrations by up to 100%. The interaction is pharmacokinetic, involving enzyme inhibition, and can lead to accumulation of lamotrigine to toxic levels.

The elevated lamotrigine concentration increases the risk of dose-related adverse effects, particularly serious skin rashes including Stevens-Johnson syndrome and toxic epidermal necrolysis, which can be life-threatening. It also increases the risk of other dose-dependent side effects, such as dizziness, ataxia, diplopia, and somnolence. The onset of rash may occur early in treatment and can progress rapidly, so heightened vigilance is needed.

When valproic acid and lamotrigine are co-prescribed, the starting dose of lamotrigine should be reduced to approximately half of the standard initiating dose, and the subsequent titration should be slower, with increments every alternate week. The dose of valproic acid may also need adjustment. Prescribers should monitor the patient for signs of rash, fever, or other hypersensitivity reactions, especially during the first few months of therapy. Routine monitoring of lamotrigine serum concentrations can be helpful, though not universally available. If a rash develops, lamotrigine should be discontinued immediately. This combination is best managed by a specialist with expertise in epilepsy.

This interaction is well established through pharmacokinetic studies and clinical reports, and it is widely referenced in national guidelines. The current Summary of Product Characteristics for lamotrigine recommends halving the maintenance dose when given with valproic acid. No specific citations are provided, but this is a well-recognised interaction.